BriaCell issues letter to shareholders

BriaCell (BCTX) Therapeutics issues a letter to shareholders from Dr. William Williams, BriaCell’s President and CEO. “I am writing this letter to share our excitement regarding the recent milestones achieved in our pivotal Bria-IMT Phase 3 study, impressive survival benefit updates from our Bria-IMT Phase 2 study, and highly encouraging early data of our newest Bria-OTS Phase 1/2 personalized cancer treatment study. We firmly believe that our novel immunotherapy candidates have the potential to transform the treatment landscape for cancer patients. Bria-IMT, an off-the-shelf targeted cell-based immunotherapy for the treatment of metastatic breast cancer, is a genetically engineered human breast cancer cell line designed to stimulate the immune system to attack cancer… Recently, we announced that over 75 patients have been enrolled at 54 active clinical sites across 15 states… We continue to follow patients’ survival and clinical data from the Phase 2 portion of the study. We recently reported Phase 2 survival data superior to reported standard of care including TRODELVY in similar hormone receptor positive metastatic breast cancer patients. Clinical benefit was observed in 83% of evaluable patient sub-group who were treated with our Phase 3 formulation, which we believe will translate to favorable outcomes for our ongoing Phase 3 patients… Bria-OTS or Off-The-Shelf is our proprietary approach designed to maximize patient response by matching each patient’s human leukocyte antigen to provide personalized immunotherapy.,, We recently confirmed 100% resolution of a lung metastasis with Bria-OTS monotherapy at 4 month follow-up in a hormone receptor positive breast cancer patient who was first noted to have tumor resolution at 2 months. This patient remains on study with stable disease elsewhere. This is a remarkable response in such a short period of time.”